Descripción de la empresa
Century Therapeutics, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry where it develops allogeneic cell therapies aimed at treating solid tumors, hematological malignancies, and autoimmune diseases. The company's core business revolves around its lead product candidate, CNTY-813, which is an iPSC-derived beta islet cell replacement therapy engineered for specific medical applications. As of the latest data, the entity maintains a market capitalization of $406.17M and employs a workforce of 78 individuals to execute its research and development initiatives. With an annual revenue of $109.16M, the company's valuation reflects a mid-sized biotechnology firm that has generated significant top-line income despite not yet achieving profitability. These financial metrics indicate a substantial operational footprint relative to typical early-stage biotech companies, suggesting a level of commercial maturity that allows for continued investment in pipeline advancement while managing cash reserves.
Salud financiera
The financial performance of Century Therapeutics over the trailing twelve months demonstrates a revenue figure of $109.16M alongside a net income of $-9,580,000 and an EBITDA of $-1,939,000. The substantial disparity between the reported revenue and the negative net income reveals a cost structure characterized by high operating expenses, likely driven by research costs and clinical trial expenditures common in the biotechnology sector. The company reported a free cash flow of $-97,213,000, which indicates a significant burn rate and limited financial flexibility to fund operations without external capital raising or asset monetization. Analysis of the three primary margins shows a gross margin of 12.4%, an operating margin of -13.8%, and a profit margin of -8.8%, all of which suggest that the company is currently in a loss-making phase where revenue does not yet cover the full scope of operational and production costs. The balance sheet holds $117.11M in cash against $43.56M in debt, resulting in a debt-to-equity ratio of 27.41, which implies a conservative liquidity stance regarding absolute debt levels but highlights a high leverage ratio relative to shareholder equity. Furthermore, the current ratio stands at 5.97, indicating that the company possesses more than five times the current assets required to cover its short-term liabilities, thereby signaling robust short-term liquidity. The return on equity is -6.0% and the return on assets is -3.3%, metrics that reveal management has not yet generated positive returns on the capital deployed or the assets owned, a typical characteristic for biotechnology firms still in the development phase of their commercial products.
Evaluación de valoración
Valuation metrics for Century Therapeutics present a complex picture due to the absence of positive earnings, with a P/E ratio (TTM) listed as N/A and a forward P/E of -4.26. The difference between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing the stock based on future potential earnings rather than current profitability, a common valuation methodology for pre-revenue or loss-making biotechnology companies. The price-to-book ratio is recorded at 1.24, which indicates that the market values the company at a slight premium of 24% over its net book value, suggesting confidence in the intangible assets and pipeline value beyond the balance sheet figures. Alternative valuation metrics such as the price-to-sales ratio of 3.72 and an EV/EBITDA of -171.54 provide context for valuation; the high multiple on sales suggests investors are willing to pay a significant price per dollar of revenue, while the negative EV/EBITDA confirms that earnings are currently negative. Price action over the last year shows a 52-week high of $3.04 and a 52-week low of $0.34, meaning the stock is currently trading well below its peak performance but significantly above its lowest point, reflecting volatility and market sentiment shifts. The beta value of 1.67 indicates that the stock exhibits higher price volatility than the broader market, moving 67% more than the average stock in response to market fluctuations, which aligns with the high-risk profile of small-cap biotechnology equities.
Growth & Income
The growth profile of Century Therapeutics is defined by a revenue growth (YoY) of -100.0% and an earnings growth (YoY) that is N/A due to prior period adjustments or lack of comparable positive earnings. The fact that revenue growth is negative while earnings growth is not applicable implies a drastic contraction in top-line sales or a change in accounting periods, necessitating a reinvestment of any remaining earnings into growth initiatives rather than distribution. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are retained within the business to fund research, development, and operational scaling rather than being distributed to shareholders. The overall growth and income profile characterizes Century Therapeutics as a high-risk, non-income-generating asset where the primary value proposition lies in the potential future commercialization of its cell therapy pipeline rather than current cash distributions or consistent revenue expansion.